Sage Therapeutics (SAGE) Q3 2024 earnings summary

Executive summary

• Strategic reorganization in October 2024 included a 33% workforce reduction to strengthen the balance sheet, focus on ZURZUVAE for postpartum depression (PPD), and discontinue ZULRESSO after December 31, 2024.

• No further development of zuranolone for major depressive disorder (MDD) in the U.S.; resources prioritized for PPD and early-stage pipeline opportunities.

• ZURZUVAE positioned as a first-line therapy for PPD, with strong growth, broad prescriber adoption (especially among OB-GYNs), and over 90% payor coverage.

• Collaboration with Biogen on SAGE-324 terminated; Sage regains full rights and will evaluate future indications.

• Net loss for the nine months ended September 30, 2024, was $304.9M, with an accumulated deficit of $2.9B.

Financial highlights

• ZURZUVAE generated $22.1M in total revenue in Q3 2024, with $11M recognized as collaboration revenue, up 49% from Q2; total Q3 2024 revenue was $11.9M, up from $2.7M in Q3 2023.

• Approximately 2,000 prescriptions filled in Q3 2024, representing 40% growth over Q2.

• R&D expenses were $54.6M and SG&A expenses were $53.2M in Q3 2024, both down significantly year-over-year.

• Net loss for Q3 2024 was $93.6M, improved from $201.6M in Q3 2023; net loss per share was $1.53 vs. $3.37 year-over-year.

• Cash, cash equivalents, and marketable securities totaled $569M as of September 30, 2024, expected to fund operations into 2026.

Outlook and guidance

• Operating expenses expected to decrease in 2025 due to reorganization; updated cash runway guidance forthcoming.

• Cash runway anticipated to extend into 2026, excluding potential savings from reorganization.

• No additional milestone payments from collaborations anticipated for the remainder of 2024.

• Top-line data from the phase II DIMENSION study in Huntington's disease expected late 2024.